Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas.

Sun Loo, Andrew Lim, Sze Ting Lee, Andrew Grigg

Clinical lymphoma, myeloma & leukemia 2023 Mar

filter terms:

In patients with relapsed/refractory lymphoma after first line therapy, chemosensitivity to salvage chemotherapy is the main determinant of outcome pre-autologous stem cell transplant . With novel therapies not yet widely available and poor responses to conventional dose salvage therapy such as ifosfamide, carboplatin, and etoposide (ICE) in patients with early relapse within 12 months and primary refractory disease, there is capacity to dose intensify ifosfamide and etoposide (augmented ICE). We retrospectively evaluated patients who received augmented ICE between 2010 and 2020 and report on response, deliverability, toxicities, and outcome. Patients were transplant eligible with diffuse large-B cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) with refractory disease or relapse within 12 months. Dose of augmented ICE versus standard ICE was ifosfamide 10 versus 5 g/m2 and etoposide 600 versus 300 mg/m2. Carboplatin dose with a calculated area under curve of 5 was unchanged. Anti-CD20 monoclonal antibody was given in patients with CD20 positive lymphoma. Responding patients who achieved complete response or partial response proceeded to transplant. Twenty-one patients with DLBCL (n = 13) and HL (n = 8) received augmented ICE. Nineteen of 21 completed 2 cycles. Overall response rates were 85% (DLBCL) and 100% (HL). Most patients required transfusion, 2 developed reversible ifosfamide encephalopathy and 86% febrile neutropenia. Eighteen patients proceeded to transplant. 5-year overall survival (OS) and progression-free survival (PFS) in DLBCL were 62% and 45%, and in HL, 100% and 88%, respectively. Augmented ICE is associated with high response rate and transplant realization at the expense of toxicity. Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.

Citation

Sun Loo, Andrew Lim, Sze Ting Lee, Andrew Grigg. Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas. Clinical lymphoma, myeloma & leukemia. 2023 Mar;23(3):e190-e194